In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters...
Read More

Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...
Read More

Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of...
Read More

This week, Berkeley Research Group (BRG) released a new whitepaper pushing back on the highly misleading claim that 340B sales are only 2 percent of annual U.S. drug sales. Citing a number of...
Read More

In case you missed it, the Atlanta Journal-Constitution analyzed data on hospital participation in the 340B program in Georgia and found that some hospitals are raking in huge profits – with no...
Read More

As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...
Read More

The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...
Read More

There is a growing body of research on the impact of health care provider consolidation on overall health care spending. In case you missed it, a recent issue brief from the National Institute for...
Read More

Research has shown once health care services shift from a provider’s office to a hospital, treatment costs for payers and patients increase. One way hospitals drive this site of care shift is...
Read More